Inventor · disambiguated record
Chunhong He
Also filed as: HE CHUNHONG
72 granted patents·23 pending applications·1,163 citations·filing 2005–2025
99Inventor score
Top patents by PatentIndex Score
95 records- 0199US7767675B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsINCYTE CORP·Filed 2007·Granted Aug 3, 2010·85 cites·85 claims
- 0298US11530214B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2021·Granted Dec 20, 2022·7 cites·26 claims
- 0398US11053246B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2020·Granted Jul 6, 2021·23 cites·10 claims
- 0498US10813930B2Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3INCYTE CORP·Filed 2019·Granted Oct 27, 2020·27 cites·42 claims
- 0598US10450313B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2018·Granted Oct 22, 2019·32 cites·16 claims
- 0698US10213427B2Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3INCYTE CORP·Filed 2016·Granted Feb 26, 2019·34 cites·39 claims
- 0798US10131667B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2017·Granted Nov 20, 2018·35 cites·16 claims
- 0898US10040790B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2016·Granted Aug 7, 2018·36 cites·54 claims
- 0998US9745311B2Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitorsINCYTE CORP·Filed 2016·Granted Aug 29, 2017·45 cites·22 claims
- 1098US9611267B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2013·Granted Apr 4, 2017·54 cites·4 claims
- 1198US9533984B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2014·Granted Jan 3, 2017·42 cites·6 claims
- 1297US11840534B2Substituted tricyclic compounds as FGFR inhibitorsINCYTE CORP·Filed 2021·Granted Dec 12, 2023·4 cites·15 claims
- 1397US11591338B2Pyrrolotriazine compounds as TAM inhibitorsINCYTE CORP·Filed 2020·Granted Feb 28, 2023·5 cites·4 claims
- 1497US10844069B2Pyrrolotriazine compounds as TAM inhibitorsINCYTE CORP·Filed 2019·Granted Nov 24, 2020·9 cites·19 claims
- 1597US10442810B2Pyrrolotriazine compounds as TAM inhibitorsINCYTE CORP·Filed 2018·Granted Oct 15, 2019·12 cites·25 claims
- 1697US10092570B2Heterocyclylamines as PI3K inhibitorsINCYTE CORP·Filed 2017·Granted Oct 9, 2018·17 cites·20 claims
- 1797US9981975B2Pyrrolotriazine compounds as tam inhibitorsINCYTE CORP·Filed 2017·Granted May 29, 2018·18 cites·4 claims
- 1897US9944647B2Heterocyclic compounds as LSD1 inhibitorsINCYTE CORP·Filed 2016·Granted Apr 17, 2018·30 cites·12 claims
- 1997US9730939B2Heterocyclylamines as PI3K inhibitorsINCYTE CORP·Filed 2015·Granted Aug 15, 2017·23 cites·7 claims
- 2097US9533954B2Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3INCYTE CORP·Filed 2014·Granted Jan 3, 2017·42 cites·26 claims
- 2197US9493442B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Nov 15, 2016·30 cites·47 claims
- 2297US9388185B2Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitorsINCYTE CORP·Filed 2013·Granted Jul 12, 2016·44 cites·21 claims
- 2397US8754114B2Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3YAO WENQING·Filed 2011·Granted Jun 17, 2014·49 cites·26 claims
- 2497US8461330B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsZHUO JINCONG·Filed 2010·Granted Jun 11, 2013·40 cites·25 claims
- 2596US10300051B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2016·Granted May 28, 2019·14 cites·35 claims
- 2696US9988387B2Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitorsINCYTE HOLDINGS CORP·Filed 2015·Granted Jun 5, 2018·9 cites·12 claims
- 2796US9670210B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jun 6, 2017·23 cites·16 claims
- 2896US9527835B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Dec 27, 2016·25 cites·22 claims
- 2996US9493450B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Nov 15, 2016·26 cites·33 claims
- 3096US9221824B2Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitorsINCYTE CORP·Filed 2013·Granted Dec 29, 2015·14 cites·5 claims
- 3196US8487096B2Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitorsZHUO JINCONG·Filed 2011·Granted Jul 16, 2013·15 cites·8 claims
- 3296US7776874B2Amido compounds and their use as pharmaceuticalsINCYTE CORP·Filed 2008·Granted Aug 17, 2010·27 cites·24 claims
- 3396US7304081B2Amido compounds and their use as pharmaceuticalsINCYTE CORP·Filed 2005·Granted Dec 4, 2007·42 cites·25 claims
- 3495US11433071B2Heterocyclylamines as PI3K inhibitorsINCYTE CORP·Filed 2020·Granted Sep 6, 2022·3 cites·20 claims
- 3595US11247992B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2020·Granted Feb 15, 2022·3 cites·15 claims
- 3695US10717737B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted Jul 21, 2020·7 cites·10 claims
- 3795US9944645B2Imidazotriazines and imidazopyrimidines as kinase inhibitorsINCYTE HOLDINGS CORP·Filed 2016·Granted Apr 17, 2018·15 cites·15 claims
- 3895US9695168B2Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jul 4, 2017·27 cites·63 claims
- 3995US9695180B2Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jul 4, 2017·24 cites·53 claims
- 4095US8058288B2Amido compounds and their use as pharmaceuticalsYAO WENQING·Filed 2010·Granted Nov 15, 2011·22 cites·35 claims
- 4194US11673894B2Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·4 cites·25 claims
- 4294US10472367B2Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitorsINCYTE HOLDINGS CORP·Filed 2018·Granted Nov 12, 2019·5 cites·18 claims
- 4394US10174030B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Jan 8, 2019·14 cites·29 claims
- 4494US10112950B2Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Oct 30, 2018·15 cites·58 claims
- 4594US10053465B2Pyrrolopyrimidine derivatives as TAM inhibitorsINCYTE CORP·Filed 2016·Granted Aug 21, 2018·16 cites·37 claims
- 4694US9126927B2Amido compounds and their use as pharmaceuticalsYAO WENQING·Filed 2011·Granted Sep 8, 2015·20 cites·33 claims
- 4793US11136326B2Pyrrolopyrimidine derivatives as TAM inhibitorsINCYTE CORP·Filed 2019·Granted Oct 5, 2021·6 cites·31 claims
- 4893US10640503B2Imidazopyridines and imidazopyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted May 5, 2020·7 cites·66 claims
- 4992US10800779B2Heterocyclic compounds as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted Oct 13, 2020·6 cites·34 claims
- 5092US10738052B2Imidazotriaines and imidazopyrimidines as kinase inhibitorsINCYTE CORP·Filed 2018·Granted Aug 11, 2020·3 cites·18 claims
Showing the top 50 of 95 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Chunhong He files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →